Background Implantable sensors that monitor haemodynamics over time may be useful in patients with heart failure. This multicentre study assessed the feasibility of a system that has one sensor measuring absolute pressure and another measuring mixed venous oxygen saturation (SvO 2 ). Both sensors were mounted on leads that were implanted in the right ventricle.
Introduction
Implantable sensors capable of monitoring haemodynamic changes over extended periods of time may be useful in patients with heart failure. Although some studies have demonstrated that acute haemodynamic changes in response to drug therapy are poor predictors of long-term clinical outcomes [1, 2] , it has been suggested that serial measurements, rather than isolated 'snapshots', might provide unique insight regarding pathophysiological mechanisms and responses to treatment. Other studies of titration of vasodilator dosage according to haemodynamic end-points have demonstrated important clinical improvements that may not have been possible when simply using an empirical target dose [3, 4] . Haemodynamic measurements have traditionally been restricted to cardiac catheterization laboratories and intensive care units. Measurements cannot be made easily in ambulatory settings and repeated catheterizations are limited by cumulative cost and risk. Previous studies of prototypes to demonstrate the feasibility of long-term ambulatory monitoring utilized biosensors that have been applied in rate adaptive pacemakers. The first implantable haemodynamic monitor (IHM-O) consisted of a right ventricular lead that contained a relative pressure sensor for the measurement of right ventricular pulse pressure and the derivative of pressure change (dP/dt) and an oxygen saturation sensor [5, 6] . Measurements were made in five patients over 7-16 months. While this study piloted the concept of continuous data trends, it did not measure absolute pressure. The second prototype implantable haemodynamic monitor was capable of measuring absolute pressure from a lead implanted in the pulmonary artery [7] but did not have data storage capability.
This report contains the initial experience of a multicentre study designed to assess the feasibility of a new monitoring system, the IHM-1. This upgraded system has two technological innovations which distinguish it from earlier prototypes: (1) it has a pressure sensor implanted in the right ventricle which is capable of continuous recordings of absolute pressure and, (2) it has data storage capability in a 32 k memory buffer for long-term trend analysis. The purpose of the study was to determine the feasibility of making reproducible and accurate long-term (1 year) haemodynamic recordings with the upgraded IHM-1 system.
Methods

Patient study group
The study included 21 patients recruited from the Karolinska Hospital (n=9), the University of Minnesota (n=6) and the Mid America Heart Institute (n=6). The patients ranged in age from 26 to 79 years with a mean age of 61·2 13·6 years (Table 1 ). There were 17 males and four females with New York Heart Class II (n=6) or Class III (n=15) symptoms. The aetiology of heart failure was related to ischaemic heart disease in 13 patients and to idiopathic dilated cardiomyopathy in eight. Patients had significant left ventricular systolic dysfunction with a mean ejection fraction 24·0 9·6%. Evidence of left ventricular dilation was also present with a mean left ventricular internal dimension in diastole and systole of 6·6 0·9 and 5·6 1·2 cm, respectively. Baseline haemodynamic values included a reduced cardiac index (2·0 0·6 l . min 1 . m 2 ) and elevated pulmonary capillary wedge pressure (29·4 15·6 mmHg).
Patients were excluded if they were not clinically stable, had concomitant diseases that could affect 71  M  III  20  2·10  40  6·2  6·0  2 Idiopathic  49  M  III  17  2·87  40  6·8  6·1  3 Ischaemic  71  M  III  35  2·35  27  4·5  3·5  4 Ischaemic  67  M  III  17  1·47  NA  6·5  NA  5 Ischaemic  67  M  III  17  1·48  70  6·1  NA  6 Idiopathic  60  M  III  20  1·31  47  6·5  NA  7 Ischaemic  76  M  III  23  1·77  47  5·7  5·4  8 Ischaemic  79  M  II  40  1·97  30  4·7  2·9  9 Ischaemic  77  M  III  20  1·36  40  6·3  5·4  10 Ischaemic  53  M  III  11  1·90  26  6·9  5·5  11 Idiopathic  26  F  II  10  2·30  35  7·0  NA  12 Idiopathic  62  M  III  22  1·70  22  8·0  7·6  13 Ischaemic  53  M  II  21  3·10  4  7·4  6·6  14 Idiopathic  43  M  II  10  1·80  30  7·4  7·0  15 Idiopathic  52  M  III  24  NA  31  7·8  6·5  16 Ischaemic  70  M  III  20  3·40  22  7·5  6·4  17 Idiopathic  56  F  II  25  2·40  8  7·2  6·1  18 Idiopathic  61  F  III  20  2·00  15  6·1  4·8  19 Ischaemic  79  M  III  25  1·50  27  5·9  3·8  20 Ischaemic  46  M  II  30  2·00  15  6·7  5·4  21 Ischaemic  68  F  III  23  1·40  11  6·7  6·0   Average ischaemic  61·2  17-M  6-II  24·0  2·00  29·4  6·6  5·6 patient stability or had medical indications for placement of a permanent pacemaker or defibrillator.
Patients with left bundle branch block were excluded because of concerns of causing complete heart block. Each centre obtained approval from its respective research review committee. Since this was a feasibility study, the data available from the IHM-1 were not used to guide clinical management. Patients were made aware of this restriction and informed consent was obtained from all patients prior to entry into the study.
Device description
The implantable haemodynamic monitor system (IHM-1, Model 10040, Medtronic, Inc.) investigated in this study was comprised of the monitor memory unit and two transvenous right ventricular leads (Fig. 1. ).
Patients were required to carry an external pressure reference recorder that could be downloaded to provide time stamped ambient barometric pressure. The final component of the system was an external programmer (Model 10448; Medtronic, Inc.). This was a standard personal computer that was used to program data acquisition formats and interrogated data from the implanted IHM-1 via a custom radiofrequency communication board similar to those used to access information from pacemakers. The programmer also read stored ambient pressure data from the external pressure reference recorder.
The memory of IHM-1 was a 32 k bit random access memory (RAM) component that could be set by the user to store the IHM-1 data values in a wide range of formats. Typically, for the acute testing reported here, the IHM-1 was configured to store values once every 4-12 s. These values were the medians of the beat-bybeat values measured during each 4-12 s storage interval and were subsequently evaluated against comparable reference system values recorded during the same time intervals.
One lead (Model 4327A, Medtronic, Inc.) of the IHM-1 system contained an oxygen saturation sensor placed 2·8 cm proximal to a single, distal tip electrode. This lead was typically positioned with the sensing tip near the right ventricular apex (Fig. 2) and was used for detecting the unipolar cardiac electrogram. The presence of an adequate R-wave amplitude was determined at implant using a standard pacing system analyser (PSA, Model 5311, Medtronic, Inc.). The right ventricular unipolar electrogram was used to measure R-R intervals to calculate heart rate and to synchronize sensor measurements. The oxygen saturation sensor was a ratiometric reflectance oximeter as previously described in detail [8] . In brief, oxygen saturation was measured at 2 s intervals by measuring the reflectance of red and infrared light from the ventricular blood pool immediately following the R-wave detected from the electrogram.
The second lead (Model 4328, Medtronic, Inc.) contained an absolute pressure transducer placed 3·0 cm proximal to the distal tined-tip of the lead. This lead was typically positioned with the tip in the right ventricular outflow tract (Fig. 2) or the anterior aspect of the interventricular septum. Efforts were made to keep the sensor at some distance from the oxygen saturation sensor and thereby minimize mechanical interactions. This newly developed pressure sensor was similar to a prior prototype [9] but was adapted to fit in-line in the lead rather than at the distal end. Also, this sensor had greater sensitivity, improved signal-to-noise ratio, and greater long-term electrical stability. This monitor measured absolute beat-by-beat right ventricular pressure to determine right ventricular systolic and diastolic pressure and also calculated right ventricular pulse pressure. It also simultaneously estimated pulmonary artery diastolic pressure (ePAD) from the right ventricular pressure at the time of peak positive dP/dt using methods previously validated [10] [11] [12] . 
External pressure reference
The absolute pressure sensor measured total hydrostatic pressure in the heart uncorrected for external barometric pressure. To provide physiological measurements, it was necessary to subtract ambient external pressure from the internal pressure values. Since IHM-1 was a totally implanted system, it had no source of barometric pressure to allow for correction. Thus, an external pressure reference (Model 2805, Medtronic Inc.) recorder was developed. The external pressure reference recorder measured 9·5 cm by 6·0 cm and weighed approximately 138 g. It was carried by each patient and recorded the barometric pressure once per minute and was synchronized with the IHM-1 pressure records. During follow-up visits, the IHM-1 programmer would read stored ventricular pressure and external pressure data at the same time. Correction for variation in ambient pressure was computed automatically by the IHM-1 programmer.
Sensor calibration
Oxygen saturation and absolute pressure sensors were calibrated during assembly and those individual calibration factors were stored on the programmer and automatically applied by the programmer when data was uplinked from the IHM-1. A standard report of calibrated data was generated using a custom report generation programme that accompanied the IHM-1 programmer. In all cases, the data presented were acquired using the factory calibration factors even when some corrective offset could have improved accuracy of the sensor.
Implant procedure
The IHM-1 system was implanted in the patient's left subclavicular region using standard sterile techniques used for pacemaker insertion. The two right ventricular leads were inserted via the subclavian vein and/or the internal jugular vein similar to insertion of standard transvenous pacemaker leads. Two patients required placement of the leads and IHM-1 on the right side due to obstruction of venous access from prior catheterization or left hand dominance.
Standard reference measures
Comparisons to standard references were performed to evaluate the accuracy and stability of the pressure and O 2 saturation sensors at implant (0 months) and at 2, 6 and 12 months after implant using standard commercial pressure transducers and catheterization laboratory equipment. An optical Swan-Ganz catheter (Opticath, Oximetrix, Abbott Lab, Chicago, IL) was placed in a pulmonary artery location via a brachial, internal jugular or femoral vein using standard procedures and fluoroscopic guidance to avoid dislodgment of the ventricular leads. This catheter permitted examination of pulmonary artery and right ventricular pressure as well as a fibreoptic system for measuring mixed venous oxygen saturation (SvO 2 ). External pressure transducers were adjusted to the mid-thoracic location for each patient and maintained at the same hydrostatic level whenever the position of the patient was changed. To obtain an SvO 2 , mixed venous blood samples were drawn at time points throughout the procedure and SvO 2 was determined by standard co-oximetry (IL 482 Co-oximeter systems, Instrumentation Laboratory, Lexington, MA, U.S.A.). SvO 2 blood samples were taken at supine rest, pre-exercise, peak exercise, pre-drug, and at the peak response of each drug administration. The Opticath O 2 saturation signal was continuously monitored throughout the procedure.
Invasive haemodynamic protocols
After duplicate baseline measurements, patients underwent a series of physiological and pharmacological interventions intended to assess patient responses and to 
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generate a range of pressure and SvO 2 values. These interventions included two Valsalva manoeuvres (21 patients), supine (nine patients) or seated (12 patients) bicycle exercise, dobutamine infusions (21 patients), and nitroprusside infusions (19 patients). For the Valsalva manoeuvre, patients generated an exhalation airway pressure of +40 mmHg, measured by aneroid manometer, which was held for 15-30 s. Bicycle exercise was performed on an ergometer at 0 and 25 watts each for 3 min for a total of 6 min of exercise or for 6 min at 30 watts in either the supine or seated positions. Dobutamine infusions were given by infusion pump at 2·5 to 10·0 g 1 . kg 1 . min 1 (steps of 2·5 for 5 min each) while continuously monitoring heart rate and pressure responses. Nitroprusside was given for 3 min each at 25 and 50 g . kg 1 . min 1 or until a hypotensive response dictated discontinuation.
Follow-up protocol
During the first 6 months of follow-up, patients were seen at bi-weekly clinic visits during which the stored IHM-1 data were up-linked and data storage restarted. During the second 6 months, the patients had follow-up visits every 2 to 4 weeks. Patient status was independently assessed by the patient, by the physician and by the nurse at each visit. Changes in medications and/or doses were documented on case report forms. Data was only uplinked from the IHM-1 after all assessments and therapeutic decisions were performed. Patients underwent repeated haemodynamic studies at 2, 6 and 12 months after implant.
Statistical analysis
The pressure and SvO 2 sensors were treated independently in the statistical analysis of their performance. The pressure sensor was evaluated on the ability to measure right ventricular systolic and diastolic pressures compared to standard right heart catheterization. The oxygen sensor was evaluated on the ability to measure O 2 saturation compared to blood samples. The IHM-1 value was paired in time to the reference value and the difference was calculated. That difference value was then analysed across time and provocation.
IHM-1 data were analysed using a single variable (SvO 2 ) or a two-variable (systolic and diastolic pressure) two-factor multivariate analysis of variance with time, provocation, and the time-provocation interaction as the factors. Time points included 0, 2, 6, and 12 months. Provocations included dobutamine, nitroprusside, exercise, Valsalva manoeuvres and supine rest. Sensor stability was tested with the time factor and gain was tested with the provocation factor. This analysis was able to detect approximate differences between IHM-1 and reference pressures of 1·0 mmHg and SvO 2 of 5·0% saturation units consistent with an alpha level of 0·05.
Although there was a significant time variance in the systolic and diastolic pressure data, we noted that the large number of data points in this analysis increased the power (95% confidence) of this test to detect pressure differences as small as 1·0 mmHg. Since the actual pressure differences were small (see Fig. 1b, 2b and c) and attributable to sources of variability other than average sensor error, the data were pooled and each variable was included in regression analyses of IHM-1 verses reference values. Bland-Altmann plots were created for further illustration.
Results
Patient follow-up
Patient follow-up was completed for 1·4 to 23 months with a mean follow-up of 13 months. A total of 15 patients completed 1 year of follow-up. Follow-up was not fully completed in 6 patients. Three patients underwent orthotopic heart transplant for deteriorating heart failure at 1·4, 6·3 and 11·1 months of follow-up. There were three deaths at 3·1, 5·4 and 7·0 months of followup. Two deaths were considered sudden but in the context of deteriorating heart failure, and one patient died following an episode of bradycardia. The final patient developed a pericardial effusion and had the device explanted. The patient died suddenly 2 weeks following explantation of the device. Records of adverse events and deaths were reviewed in detail with a clinical investigator's committee and no deaths were reported to be device related.
Ambulatory 24-hour Holter recordings were obtained before, one day and 3 months after implantation of the IHM-1. These revealed frequent ventricular ectopy, but there were no differences in the frequency or complexity following implantation. One patient treated with coumadin had a postoperative haematoma at the monitor site that resolved without active treatment and one patient had episodes of atrial flutter that required elective cardioversion. Of note, sensor function and monitor memory were stable during the cardioversions.
Right ventricular systolic pressure performance
Resting supine right ventricular systolic pressure values averaged 37 14 mmHg and ranged from 16 to 70 mm Hg. To assess sensor stability and reproducibility, the IHM-1 values were determined at each key steady state point during all provocations performed during the serial invasive procedures. These values were regressed on the reference values from the Swan-Ganz catheter taken at the same time points. The regression analysis of the pooled data from the 6-38 comparisons from each patient is shown in the top panel of Fig. 3 .
Overall, the IHM-1 sensor values were highly correlated (r 2 =0·91) with the reference values for all patients at all time points and during all provocations demonstrating high reproducibility and stability over the 12 months of follow-up. The second method of evaluation of the pooled data was the Bland-Altmann plot (bottom panel, Fig. 3 ), a method which takes into account the uncertainty in the reference measure and in the IHM-1 measure of pressure. The range or variance in the error values was within 2 standard deviations of the mean difference (for >90% of the paired values), further illustrating the reproducibility of the pooled pressure data across patients, provocations and time.
The regression analysis and Bland-Altmann plots also provided data on the accuracy of the IHM-1 pressure sensor. The tendency for the IHM pressure values to fall below the identity line (top panel, Fig. 3 ) of the regression plot and the negative y-intercept of the regression line indicated that the IHM sensor tended to under-estimate the reference pressure values by about 4·5 mmHg. Similarly, the Bland-Altmann plot (bottom panel, Fig. 3 ) showed a mean pressure 
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difference of 5·0 mmHg and that the difference was consistent across time and provocation. Table 2 also illustrates sensor performance by examining right ventricular systolic pressure correlations among individual patients over time for all provocations. A further assessment of sensor performance is illustrated (Table 3 ) by examining systolic pressure correlations for each provocation over time for all patients. These individual and composite analyses confirm the accuracy and stability of the IHM-1 measurements.
Two patients (#8 and #16) had failures of the pressure sensors during follow-up and therefore only had measurements performed at implant. In patient #8, the pressure sensor was replaced and measurements restarted while in patient #16 the device was removed at the time of heart transplantation. Both sensors were examined after explanation and demonstrated leakage pathways in the sensor capsule that were probably introduced during the manufacturing process. Two patients (#12 and #19) had errors in the reference catheter measurements related to incorrect positioning after changes in posture and one patient (#20) had a pressure waveform artifact that resulted in poor correlations.
Right ventricular diastolic pressure performance
Resting IHM-1 right ventricular diastolic pressure values averaged 1 7 mmHg and ranged from 9 to 27 mmHg. Regression analysis of IHM and reference values during all provocations at implant, and 2, 6, and 12 months after implant are shown in the top panel of Fig. 4 . Overall, the IHM-1 was highly correlated with reference (r 2 =0·79) demonstrating high reproducibility Partial (*) or no (**) data due to failed pressure sensor or missing pressure reference. Partial (***) or no (****) data due to failed oxygen sensor. Fig. 4 ) demonstrated that the range of variance in error values were within two standard deviations of the mean difference. Tables 2 and 3 also show right ventricular diastolic pressure correlations of the IHM-1 system compared to the reference system for individual patients and by individual provocation, respectively.
SvO 2 saturation sensor performance
During the follow-up period, there were 12 failures of the SvO 2 sensor of which 10 occurred within the first 2 months after implantation and two occurred between months 2 and 6. In each case the pattern of failure was generally similar and was characterized by progressive increases in the red and infrared signal so that the SvO 2 value read a constant value of >70% without changes during provocation such as exercise (change <10%). In patient #16, the oxygen sensor was examined at the time of heart transplantation. There was a thin fibrinous coating extending backward from the tip and covering the sensor. It was suspected but not confirmed that this fibrinous coating was responsible for this sensor malfunction.
Among the functioning sensors, resting SvO 2 values averaged 61 11% and ranged from 32 to 84%. Regression analysis of the IHM-1 and oximeter blood samples during all provocations at all time points are shown in the top panel of Fig. 5 . Overall, the IHM-1 was highly correlated to reference (r 2 =0·78) demonstrating high 
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reproducibility and stability over 12 months. The Bland-Altmann plot (bottom panel, Fig. 5 ) demonstrated that the range or variance in error values averaged 1·6% and were within two standard deviations of the mean difference. Tables 2 and 3 
Preliminary observations during long-term follow-up
The data summarized in this paper demonstrated accuracy and stability of the IHM-1 compared with standard reference measurements with recordings made over 1-2 h during follow-up catheterizations. The memory unit of the IHM-1 can also be configured for longer storage intervals, to detect long-term trends in the ambulatory setting. During follow-up periods, the IHM-1 was programmed to store the median of a 20-min storage interval. Two patient cases with longer storage intervals illustrate the potential benefit of long-term haemodynamic monitoring. Patient #20 (Fig. 6 ) experienced a progressive downhill course starting approximately 2 weeks after implant. Symptoms of heart failure were insidiously increasing associated with slight increases in right ventricular diastolic pressure and marked decreases in right ventricular systolic pressure, right ventricular pulse pressure and O 2 saturation, all suggestive of possible right heart failure. Daily fluctuations in heart rate tended to decrease as manifest by a narrowing in the 10 to 90% percentiles. There were several episodes of atrial fibrillation which resulted in marked increases in heart rate. These changes were followed by four brief hospitalizations for decompensated heart failure approximately 4 months after implant. The improvement during each hospitalization was only temporary and the patient did not stabilize until implantation of a left ventricular assist device. The left ventricular assist device was associated with improvement in all haemodynamic parameters. Subsequently, the patient underwent heart transplantation. In this case, changes in right ventricular systolic pressure and pulse pressure may have been early warning signs for significant deterioration potentially prompting more aggressive, 'pre-emptive' therapeutic interventions.
Patient #21 (Fig. 7) was clinically stable for 3 months after IHM-1 implant but then developed signs and symptoms of progressive heart failure associated with a steady increase in right ventricular systolic, right ventricular diastolic and estimated pulmonary artery Ambulatory haemodynamic monitors in heart failure 951 diastolic pressures. The patient was hospitalized for decompensated heart failure and was treated with intravenous diuretics and dobutamine. This hospitalization was associated with a dramatic improvement in clinical and haemodynamic parameters. However, the improvement in clinical signs and haemodynamics were short-lived and both quickly returned to prehospitalization values. The patient was readmitted 2 months later and again improved with intravenous diuretics and dobutamine. Subsequently, the patient collapsed and died suddenly 5 days after discharge. This case demonstrates that haemodynamic stabilization after dobutamine can be temporary. The rapid deterioration in haemodynamics may be a more sensitive and predictable measurement and could indicate the need for hospitalization.
Discussion
These data are the first demonstration of the feasibility of continuous recordings of ambulatory haemodynamics including absolute right ventricular pressure and mixed venous oxygen saturation in patients with heart failure. Of the 21 patients, there were two mechanical failures of the pressure sensor and 12 patients had malfunctioning oxygen sensors. In patients with functioning sensors, data from regression analysis and Bland-Altmann plots of mean differences demonstrated that the recordings from IHM-1 were stable, reproducible and accurate compared with standard reference right heart catheterizations. Sensor stability and accuracy in right ventricle systolic, right ventricle diastolic and mixed venous oxygen saturations was maintained for 12 months of follow-up, among individual patients and during several provocations, including the Valsalva manoeuvre, bicycle exercise and infusions of dobutamine and nitroprusside. If the failure pattern of the oxygen sensor could be corrected, implantable haemodynamic monitors could potentially be used for important studies of pathophysiological mechanisms and treatment monitoring for patients with heart failure.
The IHM-1 system tested in this study contained several technological improvements over models that have been described previously. First, IHM-1 was the first implantable monitor capable of continuously measuring absolute pressure in the right ventricle; a previous model measured right ventricular pulse pressure that did not require an external pressure reference.
The second technological improvement was a 32 k memory buffer which provided long-term trend analysis. Clearly, additional studies will be necessary to determine the clinical utility of the time trend analysis of right ventricular pressure and mixed venous oxygen saturation. However, preliminary data from patients described earlier suggest that the ability to obtain this information was technically feasible and that long-term trend analysis will probably be very different from 'snapshot' examinations. Furthermore, this innovation frees the patient from being physically connected to a monitor and is the first step towards transmission of long-term data transtelephonically.
The explanation for sensor failures has been incompletely characterized to date. Examination of the two explanted pressure sensors revealed component failures which were probably related to the manufacturing process. Oxygen sensor failure may be related to thrombosis or fibrinous overgrowth and tissue/material interface but additional studies are necessary. Previous studies [5, 7] using a similar oxygen sensor in 15 patients did not show similar failure rates. It is possible that the presence of two leads in the right ventricle, as opposed to the single right ventricle lead in the previous study, may produce lead-lead interaction that promotes fibrinous overgrowth. This problem can be addressed in future studies if both sensors are incorporated into one lead.
Patient acceptance and safety of the device were excellent. There were three deaths but these findings were not unusual in a patient group with severe heart failure. It can be expected that overall complication rates will approximate standard ventricular pacemakers but additional studies assessing a larger number of patients with heart failure will be necessary to more fully evaluate adverse event rates associated with implantable haemodynamic monitors.
Both right ventricular systolic and diastolic pressures showed an average and constant offset of approximately 5 to 6 mmHg. The offset was recognized immediately after implant and did not change over time. The mechanism of the offset has not been defined but it appeared to be related to a change in the sensor early after implantation. The IHM-1 was capable of recalibration to correct the offset but this was not done in the current study in order to evaluate the offset over time. It has also been argued that measurement of oxygen saturation in the right ventricle was not a true mixed venous specimen because of blood streaming. Ohlsson et al. [13] did, however, demonstrate that oxygen saturation in the right ventricle accurately reflected pulmonary arterial 'mixed' venous blood oxygen saturation. This was confirmed by the present data demonstrating that there was no detectable difference between the blood samples obtained from the distal port of the catheter in the pulmonary artery and the IHM-1 sensor in the right ventricle. Furthermore, the intent of the IHM-1 pilot study was less for accuracy at one period of time but rather over the extended period of time.
The clinical utility for the IHM-1 system is still unproven and is not addressed in this feasibility study. The available measurements from such an implantable system may not meet all heart failure patients' diagnostic needs. Although the device implant is relatively simple, it represents a finite risk to the patient and it is not clear that data of this type will be valuable.
In conclusion, this study demonstrates the feasibility of continuous recordings of ambulatory haemodynamics including absolute right ventricular pressure and SvO 2 in patients with heart failure. Recordings from the IHM-1 were stable, reproducible and accurate compared with standard reference right heart catheterizations over time and during a series of provocations. If the biological interface problems with the oxygen sensor can be corrected, this implantable haemodynamic monitor system might be useful for the study of pathophysiological mechanisms and treatment interventions in patients with heart failure.
